Abstract
The use of anticancer agents forms an important part for treatment of cancer of various types. Complexes with cis-platinum compounds have been used for the prevention and treatment of cancers. Quite a number of these metalcontaining complexes have been isolated, chemically prepared and characterized for the treatment of cancer. Many of these compounds display potent cytotoxic effects, although there is a considerable progress made in the design of novel anticancer agents. Some of these compounds showed strong inhibitory effects on cancer growth with a potential to become anti-cancer drugs. However, the unwanted deleterious effects hamper the common use of these agents as anticancer drugs. Nevertheless, the use of protective agents during, before or after treatment with anti-cancer agents in combination therapy has proven effective in the treatment. The results prompt the study of the biologic activities and the design of better modality for treatment and prevention of cancer. Here, we review the potential and reduction of cytotoxic properties of the prominent member of this class of metal compounds for the treatment of cancer.
Keywords: Cis-platinum, metal, 5-fluorouracil, granisetron, dexamethasone, anti-tumor, anti-cancer, combination therapy, ligands, cytotoxicity
Recent Patents on Anti-Cancer Drug Discovery
Title: Potential and Cytotoxicity of cis-Platinum Complex with Anti-tumor Activity in Combination Therapy
Volume: 1 Issue: 1
Author(s): John W. Ho
Affiliation:
Keywords: Cis-platinum, metal, 5-fluorouracil, granisetron, dexamethasone, anti-tumor, anti-cancer, combination therapy, ligands, cytotoxicity
Abstract: The use of anticancer agents forms an important part for treatment of cancer of various types. Complexes with cis-platinum compounds have been used for the prevention and treatment of cancers. Quite a number of these metalcontaining complexes have been isolated, chemically prepared and characterized for the treatment of cancer. Many of these compounds display potent cytotoxic effects, although there is a considerable progress made in the design of novel anticancer agents. Some of these compounds showed strong inhibitory effects on cancer growth with a potential to become anti-cancer drugs. However, the unwanted deleterious effects hamper the common use of these agents as anticancer drugs. Nevertheless, the use of protective agents during, before or after treatment with anti-cancer agents in combination therapy has proven effective in the treatment. The results prompt the study of the biologic activities and the design of better modality for treatment and prevention of cancer. Here, we review the potential and reduction of cytotoxic properties of the prominent member of this class of metal compounds for the treatment of cancer.
Export Options
About this article
Cite this article as:
Ho W. John, Potential and Cytotoxicity of cis-Platinum Complex with Anti-tumor Activity in Combination Therapy, Recent Patents on Anti-Cancer Drug Discovery 2006; 1 (1) . https://dx.doi.org/10.2174/157489206775246485
DOI https://dx.doi.org/10.2174/157489206775246485 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML)
Current Signal Transduction Therapy Drugs that Inhibit Tubulin Polymerization: The Particular Case of Podophyllotoxin and Analogues
Current Medicinal Chemistry - Anti-Cancer Agents New Treatment Approaches in Acute Myeloid Leukemia: Review of Recent Clinical Studies
Reviews on Recent Clinical Trials p73 as a Pharmaceutical Target for Cancer Therapy
Current Pharmaceutical Design Withdrawal Notice: Recent Developments in Anti-Cancer Activity of Compounds Containing the Thioether Group
Anti-Cancer Agents in Medicinal Chemistry Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology Bladder Cancer: A Simple Model Becomes Complex
Current Genomics Domperidone and Long QT Syndrome
Current Drug Safety Old Drugs-Current Perspectives
Current Pharmacogenomics Invasive Pulmonary Aspergillosis in Acute Leukemia: Current Issues for Pathogenesis, Diagnosis and Treatment
Current Respiratory Medicine Reviews Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry Limiting Functional Deficiency Following Stroke: Exploiting Different Stem Cell Reservoirs
Current Neuropharmacology Thiopurine S-Methyltransferase as a Pharmacogenetic Biomarker: Significance of Testing and Review of Major Methods
Cardiovascular & Hematological Agents in Medicinal Chemistry Differential Involvement of Myosin II and VI in the Spontaneous and SDF- 1-induced Migration of Adult CD133+ Hematopoietic Stem/Progenitor Cells and Leukemic Cells
Current Cancer Therapy Reviews Ocular Toxicities in Cancer Therapy: Still Overlooked
Current Cancer Therapy Reviews Histone Deacetylase Inhibitors: Molecular and Biological Activity as a Premise to Clinical Application
Current Drug Metabolism Epigenetic Regulation of Gene Expression as an Anticancer Drug Target
Current Cancer Drug Targets Synthesis, In Vitro Anticancer, Anti-Inflammatory and DNA Binding Activity of Thiazolidinedione Derivatives
Anti-Cancer Agents in Medicinal Chemistry Editorial from Guest Editor [Hot Topic:Vitamin D and Respiratory Health (Guest Editor: Adrian R. Martineau)]
Current Respiratory Medicine Reviews High-Dose Linoleic Acid Activated JAK2-STAT3 Signaling Pathway Involved in Cytokine Production and Lipogenesis in Pancreatic Exocrine Cells
Current Molecular Medicine